Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 TCR-T cells (Fujian Cancer Hospital)
- Development stage
- Unknown
- Lead developer
- Fujian Medical University Cancer Hospital
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NY-ESO-1 TCR-T cells (Fujian Cancer Hospital) is an investigational T-cell receptor (TCR) engineered T-cell therapy developed by Fujian Cancer Hospital for the treatment of NY-ESO-1-positive solid tumors. The therapy involves the genetic modification of a patient's T cells to express a high-affinity TCR specific for the New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) antigen, a cancer-testis antigen frequently expressed in various malignancies but with limited expression in normal tissues. These engineered cells are designed to recognize and eliminate tumor cells presenting NY-ESO-1 peptides in the context of HLA-A2. The treatment protocol typically includes a lymphodepleting preparative regimen (e.g., fludarabine, cyclophosphamide, and albumin-bound paclitaxel) followed by the infusion of the TCR-T cells and subsequent administration of high-dose IL-2 to support cell expansion and persistence.
- Other names
- TCR-T cells (Fujian Cancer Hospital)NY-ESO-1 targeting TCR-T cellsNY-ESO1 targeting TCR-T cellsNY-ESO 1 targeting TCR-T cells
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on NY-ESO-1 TCR-T cells (Fujian Cancer Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 TCR-T cells (Fujian Cancer Hospital).